Telemonitoring Platform for Chronic Kidney Disease
(VIEWER Trial)
Trial Summary
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.
What data supports the effectiveness of the VIEWER virtual care platform treatment for chronic kidney disease?
Research on remote patient management (RPM) for home dialysis shows that telehealth platforms can improve patient outcomes by enabling real-time monitoring and communication with healthcare providers. This approach helps detect early issues, ensures treatment compliance, and reduces patient anxiety, which could be beneficial for managing chronic kidney disease.12345
Is the telemonitoring platform for chronic kidney disease safe for humans?
The research suggests that telemedicine, including platforms like the VIEWER virtual care platform, can help improve patient safety by allowing CKD patients to communicate safety-related issues to their healthcare providers. However, some patients may face challenges using these technologies, which could impact their effectiveness in preventing safety events.678910
How does the telemonitoring platform for chronic kidney disease differ from other treatments?
The telemonitoring platform for chronic kidney disease is unique because it allows patients to monitor their health from home and communicate with healthcare professionals remotely. This approach can improve patient adherence to treatment plans and enable early detection of health issues, potentially preventing hospitalizations.111121314
What is the purpose of this trial?
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Research Team
Claudio Rigatto, MD
Principal Investigator
University of Manitoba
Eligibility Criteria
This trial is for adults over 18 with stage 5 chronic kidney disease (CKD), who are likely to need dialysis within two years. Participants or their caregivers must be able to read and speak English, give informed consent, and use the VIEWER app for self-monitoring tasks like measuring weight and blood pressure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants use the VIEWER platform for daily self-assessment and weekly symptom surveys, in addition to usual care
Control
Participants receive usual care either virtually or in person, depending on COVID-19 restrictions
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- VIEWER virtual care platform
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Manitoba
Lead Sponsor